menu
    • menu

    Company profile for TaiGen Biotechnology

    NEW Drugs in Dev: 7
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Taijing Biotechnology Co., Ltd. (hereinafter referred to as Taijing Taiwan or Taijing) was established in Taiwan in 2001. It is a research and development-oriented, product-oriented pharmaceutical research and development company dedicated to the development of anti-infective drugs. Taijing has a subsidiary in Beijing to conduct clinical trials and registration of new drugs in China. Taijing has about 70 colleagues in Taiwan a...
    Taijing Biotechnology Co., Ltd. (hereinafter referred to as Taijing Taiwan or Taijing) was established in Taiwan in 2001. It is a research and development-oriented, product-oriented pharmaceutical research and development company dedicated to the development of anti-infective drugs. Taijing has a subsidiary in Beijing to conduct clinical trials and registration of new drugs in China. Taijing has about 70 colleagues in Taiwan and Beijing, of which about 80 are R&D personnel.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TaiGen BiotechnologyTaiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    7th Floor, No.138, Xinming Road, Neihu District, Taipei 114, Taiwan
    Telephone
    Telephone
    886-2-8177-7020
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.taigenbiotech.com/tw
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Insilico, TaiGen Start Phase I Trial of ISM4808 for CKD Anemia
    Insilico, TaiGen Start Phase I Trial of ISM4808 for CKD Anemia

    06 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/insilico-and-taigen-achieve-milestone-in-collaboration-out-licensed-ckd-anemia-candidate-ism4808-completes-first-human-enrollment-and-dosing-in-phase-i-clinical-trial-302706605.html

    PR NEWSWIRE
    06 Mar 2026
    Share Share
    Insilico & TaiGen Achieves License Agreement for CKD
    Insilico & TaiGen Achieves License Agreement for CKD

    12 Dec 2025

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/insilico-medicine-and-taigen-achieves-license-agreement-to-develop-and-commercialize-ai-driven-phd-inhibitor-for-anemia-of-chronic-kidney-disease-ckd-302640098.html

    PR NEWSWIRE BIO
    12 Dec 2025
    Share Share
    TaiGen’s partner, Joincare completes influenza antiviral TG-1000 phase III study
    TaiGen’s partner, Joincare completes influenza antiviral TG-1000 phase III study

    19 Apr 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168640&sid=2

    PHARMABIZ
    19 Apr 2024
    Share Share
    TaiGen Successfully Completes TG-1000 Phase III Study
    TaiGen Successfully Completes TG-1000 Phase III Study

    17 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taigen-successfully-completes-tg-1000-phase-iii-study-302120368.html

    PR NEWSWIRE
    17 Apr 2024
    Share Share
    TaiGen Enters Exclusive License Agreement with YSP
    TaiGen Enters Exclusive License Agreement with YSP

    10 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taigen-enters-exclusive-license-agreement-with-ysp-301953054.html

    PR NEWSWIRE
    10 Oct 2023
    Share Share
    TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China
    TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China

    22 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taigen-enters-exclusive-license-agreement-with-joincare-for-tg-1000-in-china-301778308.html

    PR NEWSWIRE
    22 Mar 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search